Amarin Corporation Plc (AMRN) 0.90 $AMRN
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations
Marketwired - Thu Nov 06, 3:04PM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on company operations.
AMRN: 0.90 (-0.04)
Amarin to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November 6, 2014
ACCESSWIRE - Wed Nov 05, 3:56PM CST
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / November 5, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, November 6, 2014 at 4:30 PM Eastern Time.
AMRN: 0.90 (-0.04)
Amarin to Report Third Quarter 2014 Results and Host Conference Call on November 6, 2014
Marketwired - Thu Oct 30, 6:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2014 financial results and provide an operational update on Thursday, November 6, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's third quarter 2014 financial results earlier that day.
AMRN: 0.90 (-0.04)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 1.59 (unch), BIIB: 320.75 (-2.72), AMRN: 0.90 (-0.04), UTHR: 124.21 (-1.12), NLNK: 32.15 (-2.54)
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
PR Newswire - Mon Sep 22, 7:40AM CDT
The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 751.48, up 0.10%, with the index gaining 6.95% in the previous three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free research on these five companies can be accessed at:
SGYP: 3.16 (+0.18), ENZN: 1.11 (+0.11), AMRN: 0.90 (-0.04), ALKS: 51.00 (-0.03), ARRY: 3.88 (+0.02)
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
MDVN: 112.77 (+7.82), OREX: 3.85 (-0.05), AVNR: 13.02 (-0.19), GILD: 106.45 (-0.49), AMRN: 0.90 (-0.04), NPSP: 27.49 (+0.15), CELG: 106.45 (-0.69)
Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study
Marketwire - Tue Sep 16, 12:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study. This multinational, prospective, randomized, double-blind, placebo-controlled study is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels.
AMRN: 0.90 (-0.04)
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
BIIB: 320.75 (-2.72), GILD: 106.45 (-0.49), AMRN: 0.90 (-0.04), AMGN: 160.25 (-0.10)
Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Fri Sep 12, 10:39AM CDT
Shares of Amarin (AMRN) plummeted Friday after the FDA denied Amarin's appeal to reinstate Special Protocol Assessment status on a phase III study of the company's prescription fish-oil pill Vascepa.
AMRN: 0.90 (-0.04)
Investors look to Lighten Up on Shares of Amarin, Shares Down 20.4% (AMRN)
Comtex SmarTrend(R) - Fri Sep 12, 10:08AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 20.4% to $1.44 on 2.4x average daily volume. Amarin has traded 6.8 million shares thus far today, vs. average volume of 2.9 million shares per day. The stock has underperformed the Dow (-20.4% to the Dow's -0.1%) and underperformed the S&P 500 (-20.4% to the S&P's -0.2%) during today's trading.
AMRN: 0.90 (-0.04)
Why Amarin Corporation plc Stock Cratered
George Budwell, The Motley Fool - Motley Fool - Fri Sep 12, 9:28AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin Corporation are down over 20%...
AMRN: 0.90 (-0.04), GSK: 44.91 (+0.16)
Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
at The Street - Fri Sep 12, 8:43AM CDT
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
AMRN: 0.90 (-0.04)
Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal
Marketwire - Fri Sep 12, 8:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Office of New Drugs (OND) within the U.S. Food and Drug Administration (FDA) has denied Amarin's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement. Amarin had previously expressed that while it believes strongly in its legal, scientific and regulatory appeal arguments that it would be an uphill battle to achieve an SPA agreement reinstatement. Amarin continues to believe that reinstatement of this SPA agreement and approval of an indication based on the ANCHOR clinical trial results is in the best interest of patient care and is evaluating OND's response and potential next steps. Amarin has not yet received a determination from FDA on the pending ANCHOR supplemental new drug application (sNDA).
AMRN: 0.90 (-0.04)
Notice to Investors in Amarin Corp. plc's (AMRN) July 10, 2013 Public Offering: Wolf Popper LLP Announces Anticipated Filing of Amended Complaint Against Amarin Corp. plc (NASDAQ: AMRN)
PR Newswire - Tue Sep 09, 10:47AM CDT
Wolf Popper LLP, lead counsel in the In re Amarin Corp. plc Securities Litigation, pending in the U.S. District Court for the District of New Jersey (Civil Action No. 13-cv-06663), is scheduled to file an amended complaint in the class action on September 19, 2014. That complaint will assert claims against Amarin and individual defendants arising out of the federal securities laws. The allegations in the action relate to defendants' alleged misrepresentations with respect to prospects for FDA approval of Amarin's Vascepa drug for the ANCHOR indication.
AMRN: 0.90 (-0.04)
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label
at The Street - Mon Sep 08, 6:00AM CDT
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
AMRN: 0.90 (-0.04), AMGN: 160.25 (-0.10), SNY: 45.69 (-0.17), KERX: 16.73 (-0.47)
Is Amarin Corporation (AMRN) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:39AM CDT
Amarin Corporation has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat.
AMRN: 0.90 (-0.04)
Amarin to Present at the Rodman & Renshaw 2014 Global Investment Conference
Marketwire - Wed Sep 03, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Rodman & Renshaw 2014 Global Investment Conference on Wednesday, September 10, 2014, at 2:05 p.m. ET.
AMRN: 0.90 (-0.04)
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
OREX: 3.85 (-0.05), GILD: 106.45 (-0.49), CPRX: 2.73 (-0.09), ALIM: 5.06 (-0.04), AMRN: 0.90 (-0.04), ADHD: 3.75 (-0.12), SNSS: 1.63 (-0.05), NPSP: 27.49 (+0.15), LPCN: 3.95 (-0.21), DSCO: 1.54 (-0.10), XOMA: 3.81 (-0.31), KERX: 16.73 (-0.47)
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
AMRN: 0.90 (-0.04), VVUS: 3.33 (-0.08), ARNA: 4.26 (+0.01)
Top Swing Trade Ideas for Tuesday, August 19: Apple, Zynga, More
at The Street - Tue Aug 19, 9:17AM CDT
Apple, Amarin and Zynga are our big swing trades for today. So how should investors buy and sell?
AMRN: 0.90 (-0.04), ZNGA: 2.43 (+0.07), AAPL: 109.01 (+0.31)
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations
Marketwired - Thu Nov 06, 3:04PM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on company operations.
AMRN: 0.90 (-0.04)
Amarin to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November 6, 2014
ACCESSWIRE - Wed Nov 05, 3:56PM CST
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / November 5, 2014 / Amarin Corporation plc (NASDAQ:AMRN) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, November 6, 2014 at 4:30 PM Eastern Time.
AMRN: 0.90 (-0.04)
Amarin to Report Third Quarter 2014 Results and Host Conference Call on November 6, 2014
Marketwired - Thu Oct 30, 6:03AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2014 financial results and provide an operational update on Thursday, November 6, at 4:30 p.m. ET. The conference call will follow the anticipated release of the company's third quarter 2014 financial results earlier that day.
AMRN: 0.90 (-0.04)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 1.59 (unch), BIIB: 320.75 (-2.72), AMRN: 0.90 (-0.04), UTHR: 124.21 (-1.12), NLNK: 32.15 (-2.54)
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma
PR Newswire - Mon Sep 22, 7:40AM CDT
The US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 751.48, up 0.10%, with the index gaining 6.95% in the previous three months. Investor-Edge has initiated coverage on the following equities: Array BioPharma Inc. (NASDAQ: ARRY), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Alkermes PLC (NASDAQ: ALKS), Amarin Corporation PLC (NASDAQ: AMRN), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free research on these five companies can be accessed at:
SGYP: 3.16 (+0.18), ENZN: 1.11 (+0.11), AMRN: 0.90 (-0.04), ALKS: 51.00 (-0.03), ARRY: 3.88 (+0.02)
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
MDVN: 112.77 (+7.82), OREX: 3.85 (-0.05), AVNR: 13.02 (-0.19), GILD: 106.45 (-0.49), AMRN: 0.90 (-0.04), NPSP: 27.49 (+0.15), CELG: 106.45 (-0.69)
Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study
Marketwire - Tue Sep 16, 12:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study. This multinational, prospective, randomized, double-blind, placebo-controlled study is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels.
AMRN: 0.90 (-0.04)
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.
BIIB: 320.75 (-2.72), GILD: 106.45 (-0.49), AMRN: 0.90 (-0.04), AMGN: 160.25 (-0.10)
Why Amarin (AMRN) Stock Is Plummeting Today
at The Street - Fri Sep 12, 10:39AM CDT
Shares of Amarin (AMRN) plummeted Friday after the FDA denied Amarin's appeal to reinstate Special Protocol Assessment status on a phase III study of the company's prescription fish-oil pill Vascepa.
AMRN: 0.90 (-0.04)
Investors look to Lighten Up on Shares of Amarin, Shares Down 20.4% (AMRN)
Comtex SmarTrend(R) - Fri Sep 12, 10:08AM CDT
Amarin (NASDAQ:AMRN) is one of today's worst performing low-priced stocks, down 20.4% to $1.44 on 2.4x average daily volume. Amarin has traded 6.8 million shares thus far today, vs. average volume of 2.9 million shares per day. The stock has underperformed the Dow (-20.4% to the Dow's -0.1%) and underperformed the S&P 500 (-20.4% to the S&P's -0.2%) during today's trading.
AMRN: 0.90 (-0.04)
Why Amarin Corporation plc Stock Cratered
George Budwell, The Motley Fool - Motley Fool - Fri Sep 12, 9:28AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amarin Corporation are down over 20%...
AMRN: 0.90 (-0.04), GSK: 44.91 (+0.16)
Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
at The Street - Fri Sep 12, 8:43AM CDT
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
AMRN: 0.90 (-0.04)
Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal
Marketwire - Fri Sep 12, 8:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Office of New Drugs (OND) within the U.S. Food and Drug Administration (FDA) has denied Amarin's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement. Amarin had previously expressed that while it believes strongly in its legal, scientific and regulatory appeal arguments that it would be an uphill battle to achieve an SPA agreement reinstatement. Amarin continues to believe that reinstatement of this SPA agreement and approval of an indication based on the ANCHOR clinical trial results is in the best interest of patient care and is evaluating OND's response and potential next steps. Amarin has not yet received a determination from FDA on the pending ANCHOR supplemental new drug application (sNDA).
AMRN: 0.90 (-0.04)
Notice to Investors in Amarin Corp. plc's (AMRN) July 10, 2013 Public Offering: Wolf Popper LLP Announces Anticipated Filing of Amended Complaint Against Amarin Corp. plc (NASDAQ: AMRN)
PR Newswire - Tue Sep 09, 10:47AM CDT
Wolf Popper LLP, lead counsel in the In re Amarin Corp. plc Securities Litigation, pending in the U.S. District Court for the District of New Jersey (Civil Action No. 13-cv-06663), is scheduled to file an amended complaint in the class action on September 19, 2014. That complaint will assert claims against Amarin and individual defendants arising out of the federal securities laws. The allegations in the action relate to defendants' alleged misrepresentations with respect to prospects for FDA approval of Amarin's Vascepa drug for the ANCHOR indication.
AMRN: 0.90 (-0.04)
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label
at The Street - Mon Sep 08, 6:00AM CDT
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
AMRN: 0.90 (-0.04), AMGN: 160.25 (-0.10), SNY: 45.69 (-0.17), KERX: 16.73 (-0.47)
Is Amarin Corporation (AMRN) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:39AM CDT
Amarin Corporation has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat.
AMRN: 0.90 (-0.04)
Amarin to Present at the Rodman & Renshaw 2014 Global Investment Conference
Marketwire - Wed Sep 03, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Rodman & Renshaw 2014 Global Investment Conference on Wednesday, September 10, 2014, at 2:05 p.m. ET.
AMRN: 0.90 (-0.04)
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
OREX: 3.85 (-0.05), GILD: 106.45 (-0.49), CPRX: 2.73 (-0.09), ALIM: 5.06 (-0.04), AMRN: 0.90 (-0.04), ADHD: 3.75 (-0.12), SNSS: 1.63 (-0.05), NPSP: 27.49 (+0.15), LPCN: 3.95 (-0.21), DSCO: 1.54 (-0.10), XOMA: 3.81 (-0.31), KERX: 16.73 (-0.47)
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
AMRN: 0.90 (-0.04), VVUS: 3.33 (-0.08), ARNA: 4.26 (+0.01)
Top Swing Trade Ideas for Tuesday, August 19: Apple, Zynga, More
at The Street - Tue Aug 19, 9:17AM CDT
Apple, Amarin and Zynga are our big swing trades for today. So how should investors buy and sell?
AMRN: 0.90 (-0.04), ZNGA: 2.43 (+0.07), AAPL: 109.01 (+0.31)
